Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations.

Nixon AML, Duque A, Yelle N, McLaughlin M, Davoudi S, Pedley NM, Haynes J, Brown KR, Pan J, Hart T, Gilbert PM, Singh SK, O'Brien CA, Sidhu SS, Moffat J.

Sci Rep. 2019 Jan 29;9(1):842. doi: 10.1038/s41598-018-37462-1.

2.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.

Maccalli C, Parmiani G, Ferrone S.

Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13. Review.

PMID:
28287848
3.

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.

Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C.

J Immunol. 2014 Jan 1;192(1):523-32. doi: 10.4049/jimmunol.1301342. Epub 2013 Nov 25.

4.

Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.

Morrison BJ, Steel JC, Morris JC.

BMC Cancer. 2018 Apr 26;18(1):469. doi: 10.1186/s12885-018-4389-3.

5.

Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma.

Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A, Patrizii M, Warnken U, Schnölzer M, Ciolfi A, Di Stefano C, Biffoni M, Ricci-Vitiani L, Pallini R, De Maria R.

Cell Stem Cell. 2017 Jul 6;21(1):35-50.e9. doi: 10.1016/j.stem.2017.04.009. Epub 2017 Jun 9.

6.

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT.

Cancer Res. 2008 Dec 1;68(23):9703-11. doi: 10.1158/0008-5472.CAN-08-3084.

7.

Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance.

López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C, García-Carrancá A.

BMC Cancer. 2012 Jan 28;12:48. doi: 10.1186/1471-2407-12-48.

8.

Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.

Takeda R, Hirohashi Y, Shen M, Wang L, Ogawa T, Murai A, Yamamoto E, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nishidate T, Okita K, Kutomi G, Sato N, Takemasa I, Torigoe T.

Biochem Biophys Res Commun. 2017 Apr 8;485(3):651-657. doi: 10.1016/j.bbrc.2017.02.081. Epub 2017 Feb 20.

PMID:
28219643
9.

Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.

Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN.

J Exp Med. 2013 Dec 16;210(13):2851-72. doi: 10.1084/jem.20131195. Epub 2013 Dec 9.

10.

Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.

Morita R, Hirohashi Y, Torigoe T, Ito-Inoda S, Takahashi A, Mariya T, Asanuma H, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Kutomi G, Mizuguchi T, Terui T, Ishitani K, Hashino S, Kondo T, Minagawa N, Takahashi N, Taketomi A, Todo S, Asaka M, Sato N.

Clin Cancer Res. 2016 Jul 1;22(13):3298-309. doi: 10.1158/1078-0432.CCR-15-1709. Epub 2016 Feb 9.

11.

In vivo imaging, tracking, and targeting of cancer stem cells.

Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W, Pajonk F.

J Natl Cancer Inst. 2009 Mar 4;101(5):350-9. doi: 10.1093/jnci/djn509. Epub 2009 Feb 24. Erratum in: J Natl Cancer Inst. 2009 Jun 3;101(11):833.

12.

Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells.

Morrison BJ, Steel JC, Morris JC.

PLoS One. 2012;7(11):e49752. doi: 10.1371/journal.pone.0049752. Epub 2012 Nov 13.

13.

Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells.

Shidal C, Al-Rayyan N, Yaddanapudi K, Davis KR.

Oncotarget. 2016 Dec 20;7(51):84128-84141. doi: 10.18632/oncotarget.11554.

14.

Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.

Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, Mandelboim O, Stassi G, Di Fabrizio E, Parmiani G, Moretta A, Dieli F, Kärre K, Carbone E.

J Immunol. 2013 Mar 1;190(5):2381-90. doi: 10.4049/jimmunol.1201542. Epub 2013 Jan 23.

15.

The role of phage display in therapeutic antibody discovery.

Chan CE, Lim AP, MacAry PA, Hanson BJ.

Int Immunol. 2014 Dec;26(12):649-57. doi: 10.1093/intimm/dxu082. Epub 2014 Aug 18. Review.

PMID:
25135889
16.

Differential remodeling of extracellular matrices by breast cancer initiating cells.

Raja AM, Xu S, Zhuo S, Tai DC, Sun W, So PT, Welsch RE, Chen CS, Yu H.

J Biophotonics. 2015 Oct;8(10):804-15. doi: 10.1002/jbio.201400079. Epub 2015 Jan 19.

17.

Mouse induced glioma-initiating cell models and therapeutic targets.

Kondo T.

Anticancer Agents Med Chem. 2010 Jul;10(6):471-80.

PMID:
20879984
18.

Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells.

Matsui T, Kinugasa Y, Tahara H, Kanakura Y, Takakura N.

Am J Pathol. 2013 May;182(5):1790-9. doi: 10.1016/j.ajpath.2013.01.019. Epub 2013 Mar 7.

PMID:
23473746
19.

Heterogeneity of tumor cells in terms of cancer-initiating cells.

Morii E.

J Toxicol Pathol. 2017 Jan;30(1):1-6. doi: 10.1293/tox.2016-0056. Epub 2016 Sep 25. Review.

20.

Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.

Fan CW, Chen T, Shang YN, Gu YZ, Zhang SL, Lu R, OuYang SR, Zhou X, Li Y, Meng WT, Hu JK, Lu Y, Sun XF, Bu H, Zhou ZG, Mo XM.

Cell Death Dis. 2013 Oct 3;4:e828. doi: 10.1038/cddis.2013.337.

Supplemental Content

Support Center